# FAM219A

## Overview
FAM219A is a gene that encodes a protein belonging to the family with sequence similarity 219 member A. This protein is implicated in various biological processes, although its precise functions are not yet fully understood. FAM219A has garnered attention in medical research due to its potential role as a biomarker in several health conditions. Notably, it has been identified as a significant predictor of severe outcomes in COVID-19 patients, where its expression levels correlate with the likelihood of ICU admission (PenriceRandal2022Blood). Additionally, FAM219A expression is affected in NGLY1 deficiency, suggesting a possible involvement in the cellular pathways disrupted by this genetic disorder (Rauscher2021Patientderived). In oncology, particularly prostate cancer, FAM219A has been associated with improved diagnostic performance when combined with PSA levels, although its specific clinical implications in cancer diagnosis and prognosis require further investigation (MatosFilipe2024Integration).

## Clinical Significance
FAM219A has been identified as a significant biomarker in predicting severe outcomes in COVID-19 patients. A study using blood gene expression profiles found that FAM219A was the most important variable for predicting ICU admission in COVID-19 patients, as determined by a Random Forest model. This gene was highlighted for its potential interaction with the SARS-CoV-2 M protein, although its specific function remains unknown (PenriceRandal2022Blood).

In the context of NGLY1 deficiency, FAM219A expression is notably affected. The gene was found to be downregulated in NGLY1-deficient cells, and its expression levels were restored upon correction of NGLY1 mutations using CRISPR-Cas9 technology. This suggests that FAM219A may play a role in the cellular processes impacted by NGLY1 deficiency (Rauscher2021Patientderived).

In prostate cancer research, FAM219A has shown improved diagnostic performance when PSA levels are included in models, indicating its potential reliance on PSA for enhanced diagnostic accuracy. However, specific clinical significance in prostate cancer remains to be fully elucidated (MatosFilipe2024Integration).

## Interactions



## References


1. (Rauscher2021Patientderived) Patient-derived gene and protein expression signatures of NGLY1 deficiency. This article has 1 citations.

2. (MatosFilipe2024Integration) Integration of expression datasets to identify biomarkers for accurate Gleason scoring in Prostate Cancer. This article has 0 citations.

[3. (PenriceRandal2022Blood) Rebekah Penrice-Randal, Xiaofeng Dong, Andrew George Shapanis, Aaron Gardner, Nicholas Harding, Jelmer Legebeke, Jenny Lord, Andres F. Vallejo, Stephen Poole, Nathan J. Brendish, Catherine Hartley, Anthony P. Williams, Gabrielle Wheway, Marta E. Polak, Fabio Strazzeri, James P. R. Schofield, Paul J. Skipp, Julian A. Hiscox, Tristan W. Clark, and Diana Baralle. Blood gene expression predicts intensive care unit admission in hospitalised patients with covid-19. Frontiers in Immunology, September 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.988685, doi:10.3389/fimmu.2022.988685. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.988685)